Free tool
FAERS Monitor: Humira
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125057 or its brand name (Humira, Adalimumab). Reports on generic versions are filed under their own applications.
Reports
707,206
Serious
361,046
51% of reports
Hospitalization
150,085
Death reported
30,552
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective92,025
- pain49,968
- arthralgia48,831
- injection site pain47,452
- fatigue39,903
- rheumatoid arthritis36,391
- headache28,969
- nausea27,641
- diarrhoea26,024
- rash25,952
- psoriasis25,015
- pain in extremity24,719
- joint swelling23,840
- incorrect dose administered22,416
- off label use22,386
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6,016 |
| 2005 | 5,447 |
| 2006 | 1,501 |
| 2007 | 3,876 |
| 2008 | 12,338 |
| 2009 | 18,064 |
| 2010 | 9,215 |
| 2011 | 19,373 |
| 2012 | 27,620 |
| 2013 | 24,116 |
| 2014 | 48,971 |
| 2015 | 53,592 |
| 2016 | 85,177 |
| 2017 | 37,237 |
| 2018 | 42,043 |
| 2019 | 45,997 |
| 2020 | 48,439 |
| 2021 | 39,138 |
| 2022 | 78,512 |
| 2023 | 41,341 |
| 2024 | 26,912 |
| 2025 | 21,078 |
| 2026 | 11,202 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,346,953 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 36,391 | 13.6 | 13.4 | 289,169 |
| joint swellingSignal | 23,840 | 7.1 | 7.0 | 100,331 |
| psoriasisSignal | 25,015 | 6.8 | 6.7 | 100,840 |
| injection site painSignal | 47,452 | 5.3 | 5.2 | 140,422 |
| arthralgiaSignal | 48,831 | 3.8 | 3.8 | 91,708 |
| incorrect dose administeredSignal | 22,416 | 3.1 | 3.1 | 29,615 |
| pain in extremitySignal | 24,719 | 2.6 | 2.6 | 23,238 |
| painSignal | 49,968 | 2.5 | 2.5 | 44,344 |
| drug ineffectiveSignal | 92,025 | 2.2 | 2.1 | 56,708 |
| rash | 25,952 | 1.8 | 1.8 | 9,197 |
| fatigue | 39,903 | 1.6 | 1.5 | 7,732 |
| headache | 28,969 | 1.4 | 1.4 | 3,148 |
| diarrhoea | 26,024 | 1.2 | 1.2 | 918 |
| nausea | 27,641 | 1.0 | 1.0 | 43 |
| off label use | 22,386 | 0.8 | 0.7 | 1,826 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.